Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-11
2006-07-11
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S510000, C549S511000
Reexamination Certificate
active
07074821
ABSTRACT:
New taxoids of general formula (I), their preparation and pharmaceutical compositions containing them.In general formula (I),Ar represents an aryl radical,R represents a hydrogen atom or an acetyl, alkoxyacetyl or alkyl radical,R1represents a benzoyl radical or a radical of formula R2—O—CO— in which R2represents an optionally substituted alkyl radical, an alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl radical.The new products of general formula (I) have a remarkable antitumor activity.
REFERENCES:
patent: 4507217 (1985-03-01), Sears
patent: 4534899 (1985-08-01), Sears
patent: 4857653 (1989-08-01), Colin et al.
patent: 4876399 (1989-10-01), Holton et al.
patent: 4892735 (1990-01-01), Harrap
patent: 4924012 (1990-05-01), Colin et al.
patent: 5015744 (1991-05-01), Holton
patent: 5136060 (1992-08-01), Holton
patent: 5175315 (1992-12-01), Holton
patent: 5227400 (1993-07-01), Holton et al.
patent: 5229526 (1993-07-01), Holton
patent: 5243045 (1993-09-01), Holton et al.
patent: 5250683 (1993-10-01), Holton et al.
patent: 5254580 (1993-10-01), Chen et al.
patent: 5254703 (1993-10-01), Holton
patent: 5262409 (1993-11-01), Margolis et al.
patent: 5274124 (1993-12-01), Holton
patent: 5283253 (1994-02-01), Holton et al.
patent: 5284864 (1994-02-01), Holton et al.
patent: 5284865 (1994-02-01), Holton et al.
patent: 5294637 (1994-03-01), Chen et al.
patent: 5294737 (1994-03-01), Ojima
patent: 5319112 (1994-06-01), Kingston et al.
patent: 5336785 (1994-08-01), Holton
patent: 5338872 (1994-08-01), Holton et al.
patent: 5350866 (1994-09-01), Holton et al.
patent: 5384399 (1995-01-01), Holton
patent: 5399726 (1995-03-01), Holton et al.
patent: 5405972 (1995-04-01), Holton et al.
patent: 5415869 (1995-05-01), Straubinger et al.
patent: 5430160 (1995-07-01), Holton
patent: 5466834 (1995-11-01), Holton
patent: 5484809 (1996-01-01), Hostetler et al.
patent: 5489601 (1996-02-01), Holton et al.
patent: 5494683 (1996-02-01), Liversidge et al.
patent: 5532363 (1996-07-01), Holton
patent: 5532388 (1996-07-01), Bouchard et al.
patent: 5539103 (1996-07-01), Holton
patent: 5574156 (1996-11-01), Holton
patent: 5580998 (1996-12-01), Bouchard et al.
patent: 5587489 (1996-12-01), Holton et al.
patent: 5618952 (1997-04-01), Holton et al.
patent: 5635531 (1997-06-01), Chen
patent: 5637732 (1997-06-01), Holton et al.
patent: 5645988 (1997-07-01), Vande Woude et al.
patent: 5654447 (1997-08-01), Holton et al.
patent: 5670536 (1997-09-01), Durr et al.
patent: 5698582 (1997-12-01), Bastart et al.
patent: 5710287 (1998-01-01), Holton et al.
patent: 5714513 (1998-02-01), Holton et al.
patent: 5717115 (1998-02-01), Holton
patent: 5721268 (1998-02-01), Holton et al.
patent: 5723634 (1998-03-01), Holton
patent: 5723635 (1998-03-01), Durand et al.
patent: 5728687 (1998-03-01), Bissery
patent: 5728725 (1998-03-01), Holton et al.
patent: 5728850 (1998-03-01), Holton et al.
patent: 5739362 (1998-04-01), Holton et al.
patent: 5760219 (1998-06-01), Holton et al.
patent: 5760252 (1998-06-01), Holton et al.
patent: 5814658 (1998-09-01), Bouchard et al.
patent: 5840931 (1998-11-01), Bouchard et al.
patent: 6156789 (2000-12-01), Bissery et al.
patent: 6441026 (2002-08-01), Bissery
patent: 6911549 (2005-06-01), Hester et al.
patent: 0 118 316 (1984-09-01), None
patent: 0 336 841 (1989-10-01), None
patent: 0 604 910 (1994-07-01), None
patent: 0 639 577 (1995-02-01), None
patent: 0 694 539 (1996-01-01), None
patent: 0 827 745 (1998-03-01), None
patent: 0 982 028 (2000-03-01), None
patent: WO 92/09589 (1992-06-01), None
patent: WO 92/19765 (1992-11-01), None
patent: WO 93/18751 (1993-09-01), None
patent: WO 94/07878 (1994-04-01), None
patent: WO 94/10995 (1994-05-01), None
patent: WO 94/13655 (1994-06-01), None
patent: WO 94/18164 (1994-08-01), None
patent: WO 94/26253 (1994-11-01), None
patent: WO 94/26254 (1994-11-01), None
patent: WO 95/13271 (1995-05-01), None
patent: WO 96/00724 (1996-01-01), None
patent: WO 96/01259 (1996-01-01), None
T. Irving & M. Kaminski,Double Patenting: One Way, Two Way; Whose Delay?, 1 University of Baltimore Intellectual Property Law Journal 180-206 (Spring 1993).
Bissery et al.,The Taxoids, Cancer Therapeutics: Experimental and Clinical Agents 175-193 (1995).
Rowinsky et al.,The Clinical Pharmacology and Use of Antimicrotubule Agents in Cancer Chemotherapeutics, 52 Pharmac. Ther. 35-84 (1991).
English language Derwent abstract for EP 0 694 539.
Gueritte-Voegelein et al., “Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity,”J. Med. Chem.34:992-998 (1991).
Klein et al., “Synthesis of Ring B-Rearranged Taxane Analogs,”J. Org. Chem.,59: 2370-2373 (1994).
Rose, “Taxol: a Review of its Preclinical in vivo Antitumor Activity,” Anti-Cancer Drugs, 3:4, Aug. 1992, pp. 311-321.
Rose, “Preclinical Antitumor Activity of Tumors,” Taxol Science and Applications, 1995, pp. 209-235.
Vyas et al., “Paclitaxel: A Unique Tubulin Interacting Anticancer Agent,” Progress in Medicinal Chemistry, vol. 32, 1995, pp. 289-337.
Shelanski et al., “Microtubule Assembly in the Absence of Added Nucleotides,” vol. 70, No. 3, pp. 765-768 (Mar. 1973).
de Gérard Chauvièere et al., “Chimie Organiuqe Biologique,” Comptes Rendus Des Seances de L'Academie des Sciences, pp. 501-503 (Oct. 1981).
Kant et al., “A Chemoselective Approach to Functionalize the C-10 Position of 10-Deacetylbaccatin III Synthesis and Biological Properties of Novel C-10 Taxol.RTM. Analogue,” Bristol Myers Squibb Pharmaceutical Research Institute, vol. 35, No. 31, pp. 5543-5546 (Jun. 1994).
Greene et al., “Protective Groups in Organic Synthesis,” Wiley-Interscience Publication, Ch. 2, pp. 50-62 (1981).
Chen et al., “Paclitaxel Structure-Activity Relationships and Core Skeletal Rearrangements,” Chapter 18 from Taxane Anticancer Agents, pp. 247-2614 (Oct. 1994).
Kingston et al., “4.3 Chemical Reactivity,” Progress in the Chemistry of Organic Natural Products, pp. 62-81 (1993).
Rowinsky, E. et al., “The Clinical Pharmacology and Use of Antimicrotubule Agents in Cancer Chemotherapeutics,”Pharmacology&Therapeutics,vol. 52, No. 1, The Journal of The International Encyclopedia of Pharmacology and Therapeutics, (Oct. 1991).
Rowinsky, E. et al., “Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study,”J. of Clin. Oncology, vol. 9, pp. 1692-1703 (1991).
Bissery, M. et al., Abstract 2645,Proceedings of the AACR, vol. 33, p. 443 (Mar. 1992).
Commercon et al., “Improved Protection and Esterification of Precursor Taxotere® and Taxol Side Chains,” Tetrahedron Letters, 33(36):5185-5188 (1992).
Chen et al., “Serendipitous Synthesis of a Cyclopropane-Containing Taxol Analog Via Anchimeric Participation of an Unactivated Angular Methyl Group,”J. Org. Chem.,58:4520-4521 (1993).
Bissery, M., et al., “Preclinical Profile of Docetaxel (Taxotere): Efficacy as a Single Agent and in Combination,”Seminars in Oncology, vol. 22, No. 6 (Suppl 13) pp. 3-16 (1995).
Bissery, M., et al., Abstract 1599, “PreclinicalIn VivoActivity of Docetaxel Containing Combinations,”Proceedings of ASCO, vol. 14, p. 489 (1995).
Mirabelli, C., et al., “A Murine Model to Evaluate the Ability ofIn VitroClonogenic Assays to Predict the Response to TumorsIn Vivo,” Cancer Res., vol. 48, pp. 5447-5454 (1988).
Llombart-Cussac, A., et al., Proceedings of ASCO, vol. 16 (1997), Abstract No. 629.
Gelmon, K., et al., “Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients with Advanced Solid Tumors,”Journal of Clin. Oncology, vol. 18, No. 24, pp. 4098-4108 (2000).
Kurata, T., et al., “Phase I and Pharmacokinetic Study of a New Taxoid, RPR 109881A, Given as a 1-Hour Intravenous Infusion to Patients with Advanced Solid Tumors,”Journal of Clin. Oncology, vol. 18,
Bouchard Herve
Bourzat Jean-Dominique
Commercon Alain
Aventis Pharma S.A.
Finnegan Henderson Farabow Garrett & Dunner LLP
Seaman D. Margaret
LandOfFree
Taxoids, their preparation and pharmaceutical composition... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Taxoids, their preparation and pharmaceutical composition..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Taxoids, their preparation and pharmaceutical composition... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3593129